JP2017517578A - 液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用 - Google Patents
液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用 Download PDFInfo
- Publication number
- JP2017517578A JP2017517578A JP2017517210A JP2017517210A JP2017517578A JP 2017517578 A JP2017517578 A JP 2017517578A JP 2017517210 A JP2017517210 A JP 2017517210A JP 2017517210 A JP2017517210 A JP 2017517210A JP 2017517578 A JP2017517578 A JP 2017517578A
- Authority
- JP
- Japan
- Prior art keywords
- vista
- cell
- antibody
- cells
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 title claims abstract description 46
- 239000000556 agonist Substances 0.000 title claims abstract description 37
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 title claims abstract description 28
- 230000004727 humoral immunity Effects 0.000 title claims abstract description 10
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 title claims abstract 26
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 title claims abstract 26
- 230000001629 suppression Effects 0.000 title abstract description 43
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims abstract description 50
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims abstract description 50
- 238000011282 treatment Methods 0.000 claims abstract description 39
- 239000003112 inhibitor Substances 0.000 claims abstract description 32
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 22
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 13
- 229940021747 therapeutic vaccine Drugs 0.000 claims abstract description 5
- 229940021993 prophylactic vaccine Drugs 0.000 claims abstract description 4
- 229940122544 PD-1 agonist Drugs 0.000 claims abstract description 3
- 229940124060 PD-1 antagonist Drugs 0.000 claims abstract description 3
- 229940122862 PD-L1 agonist Drugs 0.000 claims abstract description 3
- 229940123751 PD-L1 antagonist Drugs 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 127
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 115
- 239000000427 antigen Substances 0.000 claims description 95
- 108091007433 antigens Proteins 0.000 claims description 95
- 102000036639 antigens Human genes 0.000 claims description 95
- 238000000034 method Methods 0.000 claims description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 74
- 201000010099 disease Diseases 0.000 claims description 72
- 206010028980 Neoplasm Diseases 0.000 claims description 66
- 208000015181 infectious disease Diseases 0.000 claims description 31
- 238000009739 binding Methods 0.000 claims description 30
- 230000027455 binding Effects 0.000 claims description 29
- 230000005764 inhibitory process Effects 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 26
- 241000282414 Homo sapiens Species 0.000 claims description 25
- 230000036755 cellular response Effects 0.000 claims description 24
- 239000012634 fragment Substances 0.000 claims description 20
- 230000001404 mediated effect Effects 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 19
- 230000004663 cell proliferation Effects 0.000 claims description 18
- 206010025323 Lymphomas Diseases 0.000 claims description 16
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 15
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 15
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 15
- 230000001965 increasing effect Effects 0.000 claims description 15
- 241001430294 unidentified retrovirus Species 0.000 claims description 15
- 230000001363 autoimmune Effects 0.000 claims description 13
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 12
- 208000035473 Communicable disease Diseases 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 12
- 239000013566 allergen Substances 0.000 claims description 11
- 239000012678 infectious agent Substances 0.000 claims description 10
- 239000012636 effector Substances 0.000 claims description 9
- 108020001507 fusion proteins Proteins 0.000 claims description 9
- 102000037865 fusion proteins Human genes 0.000 claims description 9
- 230000007170 pathology Effects 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 230000008350 antigen-specific antibody response Effects 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 230000007969 cellular immunity Effects 0.000 claims description 6
- 230000028996 humoral immune response Effects 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 238000011285 therapeutic regimen Methods 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 230000000172 allergic effect Effects 0.000 claims description 5
- 230000005875 antibody response Effects 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 230000002195 synergetic effect Effects 0.000 claims description 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 claims description 4
- 229960004308 acetylcysteine Drugs 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 230000001270 agonistic effect Effects 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
- BXXXSTYGKLXBTL-OEPZOJQVSA-L disodium;2-phosphonato-n-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienoxy]acetamide Chemical compound [Na+].[Na+].CC(C)=CCC\C(C)=C\CC\C(C)=C\CONC(=O)CP([O-])([O-])=O BXXXSTYGKLXBTL-OEPZOJQVSA-L 0.000 claims description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
- 229960004844 lovastatin Drugs 0.000 claims description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 229960003424 phenylacetic acid Drugs 0.000 claims description 2
- 239000003279 phenylacetic acid Substances 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 claims 1
- 206010024291 Leukaemias acute myeloid Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 150000001483 arginine derivatives Chemical class 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 13
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 239000012651 immune agonist Substances 0.000 abstract description 5
- 229940044680 immune agonist Drugs 0.000 abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract description 3
- 229940123189 CD40 agonist Drugs 0.000 abstract 2
- 229940122551 CD40 antagonist Drugs 0.000 abstract 1
- 229960003753 nitric oxide Drugs 0.000 abstract 1
- 229960004854 viral vaccine Drugs 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 description 65
- 210000001744 T-lymphocyte Anatomy 0.000 description 63
- 108090000623 proteins and genes Proteins 0.000 description 45
- 102000039446 nucleic acids Human genes 0.000 description 44
- 108020004707 nucleic acids Proteins 0.000 description 44
- 230000004043 responsiveness Effects 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 41
- 108090000765 processed proteins & peptides Proteins 0.000 description 40
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 39
- 150000001413 amino acids Chemical class 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 35
- 102000004196 processed proteins & peptides Human genes 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 33
- 235000001014 amino acid Nutrition 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 28
- 229920001184 polypeptide Polymers 0.000 description 28
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 27
- 102100022338 Integrin alpha-M Human genes 0.000 description 27
- 208000024891 symptom Diseases 0.000 description 26
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 23
- 230000007246 mechanism Effects 0.000 description 22
- 230000028993 immune response Effects 0.000 description 21
- 210000002865 immune cell Anatomy 0.000 description 19
- 210000004989 spleen cell Anatomy 0.000 description 19
- 208000011580 syndromic disease Diseases 0.000 description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 239000013598 vector Substances 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 108091008874 T cell receptors Proteins 0.000 description 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 12
- 125000000539 amino acid group Chemical group 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 230000009467 reduction Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 206010009944 Colon cancer Diseases 0.000 description 11
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 11
- 230000000139 costimulatory effect Effects 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 230000008506 pathogenesis Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 208000030507 AIDS Diseases 0.000 description 9
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 9
- 102100027473 Cartilage oligomeric matrix protein Human genes 0.000 description 9
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 description 9
- 230000005867 T cell response Effects 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 201000007270 liver cancer Diseases 0.000 description 9
- 208000014018 liver neoplasm Diseases 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000012707 chemical precursor Substances 0.000 description 8
- 230000002209 hydrophobic effect Effects 0.000 description 8
- 230000004957 immunoregulator effect Effects 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000003289 regulatory T cell Anatomy 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 7
- 208000034578 Multiple myelomas Diseases 0.000 description 7
- 208000026935 allergic disease Diseases 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 201000009277 hairy cell leukemia Diseases 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 210000000066 myeloid cell Anatomy 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 108091008875 B cell receptors Proteins 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 206010061598 Immunodeficiency Diseases 0.000 description 6
- 208000029462 Immunodeficiency disease Diseases 0.000 description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 description 6
- 206010038389 Renal cancer Diseases 0.000 description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 description 6
- 230000006044 T cell activation Effects 0.000 description 6
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 230000005784 autoimmunity Effects 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 201000001981 dermatomyositis Diseases 0.000 description 6
- 206010017758 gastric cancer Diseases 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 230000007813 immunodeficiency Effects 0.000 description 6
- 201000010982 kidney cancer Diseases 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 201000011549 stomach cancer Diseases 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- HOZCHTFDGMSKNK-UHFFFAOYSA-N 6-methylspiro[4.5]dec-9-ene-10-carboxylic acid Chemical compound CC1CCC=C(C(O)=O)C11CCCC1 HOZCHTFDGMSKNK-UHFFFAOYSA-N 0.000 description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 5
- 206010005003 Bladder cancer Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- 208000007465 Giant cell arteritis Diseases 0.000 description 5
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 5
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 5
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 5
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 5
- 101100182935 Penicillium citrinum MSDC gene Proteins 0.000 description 5
- 206010036105 Polyneuropathy Diseases 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 206010039710 Scleroderma Diseases 0.000 description 5
- 230000006052 T cell proliferation Effects 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000005809 anti-tumor immunity Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 238000006384 oligomerization reaction Methods 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 201000005112 urinary bladder cancer Diseases 0.000 description 5
- 206010027654 Allergic conditions Diseases 0.000 description 4
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 description 4
- 101150013553 CD40 gene Proteins 0.000 description 4
- 102100032937 CD40 ligand Human genes 0.000 description 4
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 208000009329 Graft vs Host Disease Diseases 0.000 description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 4
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
- -1 NG-nitro-L-arginine arginine derivatives Chemical class 0.000 description 4
- 206010029240 Neuritis Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 241000721454 Pemphigus Species 0.000 description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 4
- 206010042971 T-cell lymphoma Diseases 0.000 description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 229960002949 fluorouracil Drugs 0.000 description 4
- 201000003444 follicular lymphoma Diseases 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 208000019629 polyneuritis Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001177 retroviral effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 206010043207 temporal arteritis Diseases 0.000 description 4
- 239000013638 trimer Substances 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 3
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 208000023328 Basedow disease Diseases 0.000 description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 102100033668 Cartilage matrix protein Human genes 0.000 description 3
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 3
- 208000015943 Coeliac disease Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 description 3
- 208000015023 Graves' disease Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 3
- 208000000185 Localized scleroderma Diseases 0.000 description 3
- 101100317036 Mus musculus Vsir gene Proteins 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010068786 Overlap syndrome Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 206010034277 Pemphigoid Diseases 0.000 description 3
- 201000011152 Pemphigus Diseases 0.000 description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 3
- 206010061934 Salivary gland cancer Diseases 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 description 3
- 206010046851 Uveitis Diseases 0.000 description 3
- 206010047642 Vitiligo Diseases 0.000 description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 3
- 230000009830 antibody antigen interaction Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 3
- 201000000053 blastoma Diseases 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 201000008184 embryoma Diseases 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 3
- 206010023332 keratitis Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 3
- 208000021937 marginal zone lymphoma Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 description 3
- 201000002628 peritoneum cancer Diseases 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 208000005987 polymyositis Diseases 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 206010046766 uterine cancer Diseases 0.000 description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 201000002829 CREST Syndrome Diseases 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 208000011038 Cold agglutinin disease Diseases 0.000 description 2
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 2
- 241000272201 Columbiformes Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 206010015218 Erythema multiforme Diseases 0.000 description 2
- 206010015226 Erythema nodosum Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 201000003542 Factor VIII deficiency Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 206010018687 Granulocytopenia Diseases 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
- 206010073069 Hepatic cancer Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 208000031814 IgA Vasculitis Diseases 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 208000012528 Juvenile dermatomyositis Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 208000011200 Kawasaki disease Diseases 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
- 206010027982 Morphoea Diseases 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010065159 Polychondritis Diseases 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 2
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 208000033464 Reiter syndrome Diseases 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 2
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 description 2
- 102000002938 Thrombospondin Human genes 0.000 description 2
- 108060008245 Thrombospondin Proteins 0.000 description 2
- 206010043782 Thyroiditis fibrous chronic Diseases 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 2
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000007825 activation reagent Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 201000010415 childhood type dermatomyositis Diseases 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000009096 combination chemotherapy Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003246 corticosteroid Chemical group 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 201000003278 cryoglobulinemia Diseases 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 102000057058 human VSIR Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 208000019420 lymphoid neoplasm Diseases 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000009822 protein phosphorylation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 201000006845 reticulosarcoma Diseases 0.000 description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- NTNWOCRCBQPEKQ-RXMQYKEDSA-N (2r)-2-amino-5-[(n'-methylcarbamimidoyl)amino]pentanoic acid Chemical compound CN=C(N)NCCC[C@@H](N)C(O)=O NTNWOCRCBQPEKQ-RXMQYKEDSA-N 0.000 description 1
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
- 208000023761 AL amyloidosis Diseases 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- 206010001881 Alveolar proteinosis Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002216 Anaphylactoid reaction Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 102000016904 Armadillo Domain Proteins Human genes 0.000 description 1
- 108010014223 Armadillo Domain Proteins Proteins 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 208000033241 Autosomal dominant hyper-IgE syndrome Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
- 208000016778 CD4+/CD56+ hematodermic neoplasm Diseases 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010062746 Carditis Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 241000289632 Dasypodidae Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 201000004315 EAST syndrome Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010053776 Eosinophilic cellulitis Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Chemical group 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010019860 Hereditary angioedema Diseases 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000700195 Hydrochoerus hydrochaeris Species 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 206010073257 Idiopathic angioedema Diseases 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 208000023813 IgG4-related thyroid disease Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 1
- 229940123965 Immunoglobulin inhibitor Drugs 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000012411 Intermediate Filament Proteins Human genes 0.000 description 1
- 108010061998 Intermediate Filament Proteins Proteins 0.000 description 1
- 208000009388 Job Syndrome Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010023791 Large granular lymphocytosis Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000288904 Lemur Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 208000022435 Light chain deposition disease Diseases 0.000 description 1
- 208000020647 Light chain disease Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 1
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
- 208000008551 Lyme Neuroborreliosis Diseases 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 206010027910 Mononeuritis Diseases 0.000 description 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699729 Muridae Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 101100495054 Mus musculus Ccndbp1 gene Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 208000007944 Nodular Nonsuppurative Panniculitis Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 206010053869 POEMS syndrome Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 102100031950 Polyunsaturated fatty acid lipoxygenase ALOX15 Human genes 0.000 description 1
- 101710164073 Polyunsaturated fatty acid lipoxygenase ALOX15 Proteins 0.000 description 1
- 208000004347 Postpericardiotomy Syndrome Diseases 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 206010036673 Primary amyloidosis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 208000006257 Rinderpest Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- YDBYJHTYSHBBAU-YFKPBYRVSA-N S-methyl-L-methioninate Chemical compound C[S+](C)CC[C@H](N)C([O-])=O YDBYJHTYSHBBAU-YFKPBYRVSA-N 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241000288726 Soricidae Species 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Chemical group 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 206010042970 T-cell chronic lymphocytic leukaemia Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 241000283068 Tapiridae Species 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 102100029529 Thrombospondin-2 Human genes 0.000 description 1
- 102100029524 Thrombospondin-3 Human genes 0.000 description 1
- 102100029219 Thrombospondin-4 Human genes 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010047124 Vasculitis necrotising Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000026736 Weber-Christian disease Diseases 0.000 description 1
- 208000008526 Wells syndrome Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000026784 acute myeloblastic leukemia with maturation Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 208000015230 aggressive NK-cell leukemia Diseases 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003098 androgen Chemical group 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical group C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001740 anti-invasion Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000051 antiandrogen Chemical group 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000010927 atrophic thyroiditis Diseases 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000004202 carbamide Chemical group 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 230000010428 chromatin condensation Effects 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 208000017760 chronic graft versus host disease Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 206010009869 cold urticaria Diseases 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 244000000015 environmental pathogen Species 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000000262 estrogen Chemical group 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000328 estrogen antagonist Chemical group 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical group C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 206010066957 hepatosplenic T-cell lymphoma Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 208000014796 hyper-IgE recurrent infection syndrome 1 Diseases 0.000 description 1
- 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 230000008086 immune related sensitivity Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000021646 inflammation of heart layer Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000016809 linear scleroderma Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 210000001939 mature NK cell Anatomy 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical group CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 208000013734 mononeuritis simplex Diseases 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000011201 multicentric reticulohistiocytosis Diseases 0.000 description 1
- 208000037890 multiple organ injury Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000004479 myeloid suppressor cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000021766 negative regulation of B cell proliferation Effects 0.000 description 1
- 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 201000009234 osteosclerotic myeloma Diseases 0.000 description 1
- 201000003733 ovarian melanoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 208000017262 paroxysmal cold hemoglobinuria Diseases 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 239000000583 progesterone congener Chemical group 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000027223 regulation of cytokine secretion Effects 0.000 description 1
- 208000009169 relapsing polychondritis Diseases 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 108010060887 thrombospondin 2 Proteins 0.000 description 1
- 108010060803 thrombospondin 3 Proteins 0.000 description 1
- 108010060815 thrombospondin 4 Proteins 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本出願は、2014年6月11日出願の米国仮出願第62/010,736号に対する優先権を主張する。この出願は、参照によってその全体が本明細書に組み込まれる。
本発明は、必要とする対象における、VISTAが媒介する液性免疫阻害の阻害方法または無効化方法を提供し、当該方法は、例えば、B細胞免疫が抑制される癌または感染性疾患状態を有する対象における、VISTAアンタゴニストの単独投与、または別の免疫アゴニストと関連させた投与を含む。
本発明の詳細を記載する前に、下記の定義を提供する。
実施例において使用した材料及び方法
マウス.7週齢の雄性C57BL/6(B6)マウスをNational Institutes of Health(メリーランド州、ベゼスダ)から購入し、Dartmouth Medical School Animal facilityにおいて飼育し、約8〜10週齢となったところで使用した。B6へと完全に戻し交配させたiNOSノックアウトマウスの繁殖ペアは、Jackson Labs(メイン州、バーハーバー)から入手し、当該繁殖ペアは、元は、以前に説明された(Laubachら 1995)ようにして得られたものである。また、B6へと戻し交配させたものであり、報告に沿って得たVISTAノックアウト繁殖ペアは、から入手した。
この実施例は、図1の実験に関するものである。こうした実験では、脾臓細胞によるVISTAの発現は、インビボでLP−BM5が感染することで増加することが示された。図1(A)は、フローサイトメトリー分析を含むものであり、非感染野生型B6マウスまたは感染後5週間もしくは8.5週間の野生型B6マウスに由来する脾臓細胞のVISTA発現パターンを示している。割合は、VISTAの発現に陽性である細胞を示し、イタリック体である値は、VISTAに陽性である細胞のMFIを示す。図1(B)は、脾臓細胞表面のVISTAの発現であり、下記の群のCD11b+細胞のVISTAを示す。すなわち、記載の非感染マウス系または感染マウス系から、その後に精製することなく得た細胞と、5wpi−LP−BM5マウスから精製したLy6C+CD11b+脾臓細胞と、である。示されている結果パターンは、2回の追加実験を代表するものである。
この実施例は、図2の実験に関するものである。こうした実験は、Ly6C+CD11b+で精製した脾臓細胞が、B細胞増殖と、T細胞増殖とをインビトロで抑制するために、異なる機構的必要要件を有していることを示している。図2(A及びB)は、レスポンダー対抑制因子(R:S)の比を3:1とし、ナイーブB6レスポンダー脾臓細胞を、a−VISTA及びLNMMAで事前に処理したLy6C+CD11b+MDSCと混合し、(A)a−CD40及びIL−4、または(B)ConAで3日間刺激した実験の結果を示す。
この実施例は、図3の実験に関するものである。こうした実験では、レスポンダー対抑制因子(R:S)の比を3:1として、ナイーブVISTA−/−レスポンダー脾臓細胞を、α−VISTAで事前処理したLy6C+CD11b+MDSCと混合し、a−CD40及びIL−4で3日間刺激した。示されている結果パターンは、3回の追加実験を代表するものである。*はp<0.05、**はP<0.01、***はP<0.001、有意差なし(ns.)は、P>0.05であることを示す。
この実施例は、図4の実験に関するものである。こうした実験では、LP−BM5に感染後、5週間が経過した、記載の種のマウスから精製した単球性MDSC(Ly6C+CD11b+)が、ナイーブVISTA−/−脾臓細胞の増殖を異なるパターンで抑制していることを示しており、これはフローサイトメトリーによって評価したものである。CFSEで標識したVISTA−/−レスポンダー細胞を、ct−CD40+IL4の存在下(+)または非存在下(−)かつ、単球性MDSCの存在下または非存在下で3日間培養した。すなわち、(a)(−)と、(b)(+)(灰色の影付き曲線)と、(c)(+)、野生型のMDSC(黒色の開曲線)と、(d)(+)、DNMMAで処理した野生型のMDSC(黒色の開曲線)と、(e)(+)、LNMMAで処理した野生型のMDSCと、(f)(+)、INOS−/−MDSC(点線の曲線)と、(g)(+)と、(h)(+)、VISTA−/−MDSC及び野生型のMDSCの対比と、である。4日間のインキュベーションの終了時点で、すべての培養物に由来する細胞を、ct−CD19と蛍光色素が結合したmAbで染色し、FACSによってCFSE希釈も評価した。CFSE標識したVISTA−/−レスポンダーは、%=最初の増殖ピーク中の細胞の割合eであり、イタリック体の数=CFSE+細胞のMFIである。示されている結果パターンは、1回の追加実験を代表するものである。
この実施例は、図5の実験に関するものである。こうした実験では、B細胞増殖の単球性の抑制が、2つの主な機構であるiNOS/NO及びVISTAに依存することが示された。5Aの実験では、LP−BM5に感染した5w.p.の野生型マウスまたはVISTA−/−マウスから精製したLy6C+CD11b+MDSCをct−VISTA遮断抗体または対照HIg、LNMMAまたは対照DNMMAで事前に処理してから、VISTA−/−レスポンダー細胞、ct−CD40、及びIL−4と共に3日間培養した。5(B)の実験では、パネル(A)に示すものと同一の処理レジメンに、ct−VISTA及びLNMMAの両方を含む組み合わせレジメンを含めて、野生型のLy6C+CD11b+MDSCを事前処理した。レスポンダーが取り込んだ3Hチミジンのcpmによって、(A)及び(B)の両方の抑制%を計算した。示されている結果パターンは、2回の追加実験(A)及び1回の追加実験(B)を代表するものである。*は、P<0.05、**は、P<0.01、有意差なし(ns.)はP>0.05であることを示す。
LP−BM5レトロウイルスによる感染後にMDSCが増殖するため、VISTAの細胞表面発現は、感染後(p.i.)に初めて評価した。5w.p.i.の時点で、VISTA+脾臓細胞の割合は増加していなかったが、VISTAのMFIは増加し、陽性ピークの形状が変化した(図1A)。この変化は、非感染B6マウスにおいて、CD4 T細胞がVISTAを優位に発現するという報告(Wangら 2011)と、インビボでの刺激に際して増殖するCD11b+VISTA+細胞などの細胞型のさらなる存在と、の両方に一致するものであり、本明細書では、我々が報告したLP−BM5感染が、MDSCを増殖させている(我々の参考文献)。8.5w.p.i.の時点で、VISTAの発現増加は、より明白であった(図1A)。非感染B6マウスと、5w.p.i.の野生型B6マウス、VISTA−/−B6マウス、及びINOS−/−B6マウスと、に由来する細胞による、VISTA及びCD11bの同時発現をさらに染色して対比させることで、抗VISTAmAbの特異性を確認し、高度に濃縮された単球性MDSC集団における、VISTAの発現増加を実証した(図1B)(以前にLy6Cも発現していることを示した(我々の参考文献を参照のこと。本明細書では、データ未掲載)。さらに、Wangら(2011)による研究によって予測されていたように、他の主なVISTA+集団は、CD4 T細胞コンパートメントであった(データ未掲載)。
B細胞応答性に対するVISTAの作用、具体的には、MSDCによって媒介される、B細胞応答性に対するVISTAの抑制作用に基づき、VISTAアンタゴニストを単独または他の免疫活性化因子もしくは免疫アゴニストと関連させて使用してよく、具体的には、B細胞応答性の増加が治療的に望ましい状態を治療または防止するために、アゴニストである抗CD40抗体またはCD40LポリペプチドなどのCD40アゴニストなどの、液性免疫を増進するものと関連させて使用してよい。そのような状態には、具体的には、B細胞が応答する癌が含まれ、例えば、抗体応答が疾患病理に関与するか、または予防免疫もしくは治療免疫に関与するものである。そのような癌の状態の例には、限定はされないが、カルシノーマ、リンパ腫、芽細胞腫、肉腫(脂肪肉腫を含む)、神経内分泌腫瘍、中皮腫、シュワン腫(schwanoma)、髄膜腫、腺癌、黒色腫、卵巣癌、乳癌、肺癌、脳癌、消化器癌、及び白血病またはリンパ系腫瘍が含まれる。
マウスVISTA配列識別番号:1
1 mgvpavpeas sprwgtllla iflaasrglv aafkvttpys lyvcpegqna tltcrilgpv
61 skghdvtiyk twylssrgev qmckehrpir nftlqhlqhh gshlkanash dqpqkhglel
121 asdhhgnfsi tlrnvtprds glycclviel knhhpeqrfy gsmelqvqag kgsgstcmas
181 neqdsdsita aalatgaciv gilclplill lvykqrqvas hrraqelvrm dsntqgienp
241 gfettppfqg mpeaktrppl syvaqrqpse sgryllsdps tplsppgpgd vffpsldpvp
301 dspnseai
マウスVISTA配列識別番号:2
1 mgvpavpeas sprwgtllla iflaasrglv aafkvttpys lyvcpegqna tltcrilgpv
61 skghdvtiyk twylssrgev qmckehrpir nftlqhlqhh gshlkanash dqpqkhglel
121 asdhhgnfsi tlrnvtprds glycclviel knhhpeqrfy gsmelqvqag kgsgstcmas
181 neqdsdsita aalatgaciv gilclplill lvykqrqvas hrraqelvrm dssntqgien
241 pgfettppfq gmpeaktrpp lsyvaqrqps esgryllsdp stplsppgpg dvffpsldpv
301 pdspnseai
マウスVISTA配列識別番号:3
1 mgvpavpeas sprwgtllla iflaasrglv aafkvttpys lyvcpegqna tltcrilgpv
61 skghdvtiyk twylssrgev qmckehrpir nftlqhlqhh gshlkanash dqpqkhglel
121 asdhhgnfsi tlrnvtprds glycclviel knhhpeqrfy gsmelqvqag kgsgstcmas
181 neqdsdsita aalatgaciv gilclplill lvykqrqvas hrraqelvrm dssntqgien
241 pgfettppfq gmpeaktrpp lsyvaqrqps esgryllsdp stplsppgpg dvffpsldpv
301 pdspnseai
ヒトVISTA配列識別番号:4
1 mgvptaleag swrwgsllfa lflaaslgpv aafkvatpys lyvcpegqnv tltcrllgpv
61 dkghdvtfyk twyrssrgev qtcserrpir nltfqdlhlh hgghqaants hdlaqrhgle
121 sasdhhgnfs itmrnltlld sglycclvve irhhhsehrv hgamelqvqt gkdapsncvv
181 ypsssqdsen itaaalatga civgilclpl illlvykqrq aasnrraqel vrmdsniqgi
241 enpgfeaspp aqgipeakvr hplsyvaqrq psesgrhlls epstplsppg pgdvffpsld
301 pvpdspnfev i
参考文献
1.Beilharz,M.W.,L.M.Sammels,A.Paun,K.Shaw,P.van Eeden,M.W.Watson,M.L.Ashdown.2004.Timed ablation of regulatory CD4+ T cells can prevent murine AIDS progression.J.Immunol.172(8):4917−4925.
2.Bowen,J.L.,and J.K.Olson.2009.Innate immune CD11b+Gr−1+ cells,suppressor cells,affect the immune response during Theiler’s virus−induced demyelinating disease.J.Immunol.183:6971−6980.
3.Brys,L.,A.Beschin,G.Raes,G.Hassanzadeh Ghassabeh,W.Noel,J.Brandt,F.Brombacher,and P.De Baetselier.2005.Reactive oxygen species and 12/15−lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection.J.Immunol.174:6095−6104.
4.Chen,S.,S.M.F.Akbar,M.Abe,Y.Hiasa,and M.Onji.2011.Immunosuppressive functions of hepatic myeloid−derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus.Clin.Exp.Immunol.166:134−142.
5.Day C.L.,D.E.aufmann,P.Kiepiela,J.A.Brown,E.S.Moodley,S.Reddy,E.W.Mackey,J.D.Miller,A.J.Leslie,C.DePierres,Z.Mncube,J.Duraiswamy,B.Zhu,Q.Eichbaum,M.Altfeld,E.J.Wherry,E.M.Coovadia,P.J.R.Goulder,P.Klenerman,R.Ahmed,G.J.Freeman,and B.D.Walker.2006.PD−1 expression on HIV−specific T cells is associated with T−cell exhaustion and disease progression.Nature.443:350−354.
6.Gabrilovich,D.I.,and S.Nagaraj.2009.Myeloid−derived suppressor cells as regulators of the immune system.Nat.Rev.Immunol.9:162−174.
7.Garg,A.and S.A.Spector.2014.HIV type 1 gp120−induced expansion of myeloid derived suppressor cells is dependent on Interleukin 6 and suppresses immunity.J.Inf.Dis.209(3):441−451.
8.Green,K.A.,K.M.Crassi,J.D.Laman,A.Schoneveld,R.R.Strawbridge,T.M.Foy,R.J.Noelle,and W.R.Green.1996.Antibody to the ligand for CD40(gp39)inhibits murine AIDS−associated splenomegaly,hypergammaglobulinemia,and immunodeficiency in disease−susceptible C57BL/6 mice.J.Virol.70:2569−2575
9.Green,K.A.,W.J.Cook,and W.R.Green.2013.Myeloid−derived suppressor cells in murine retrovirus−induced AIDS inhibit T−and B−cell responses in vitro that are used to define the immunodeficiency.J.Virol.87(4):2058−71.
10.Jeisy−Scott,V.,W.G.Davis,J.R.Patel,J.B.Bowzard,W.Shieh,S.R.Zaki,J.M.Katz,and S.Sambhara.2011.Increased accumulation and Th2 biased response to influenza A virus infection in the absence of TLR7 in mice.PLoS One.6(9):1−12.
11.Klinken,S.P.,T.N.Fredrickson,J.W.Hartley,R.A.Yetter,and H.C.Morse III.1988.Evolution of B cell lineage lymphomas in mice with a retrovirus−induced immunodeficiency syndrome,MAIDS.J.Immunol.140:1123−1131.
12.LaFace,D.,and J.Talmadge.2011.Meeting report:regulatory myeloid cells.Int.Immunopharmacol.11:780−782.
13.Laubach,V.E.,E.G.Shesely,O.Smithies,P.A.Sherman.1995.Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide−induced death.Proc.Natl.Acad.Sci.U.S.A.92:10688−10692.
14.LeMercier,L.,W.Chen,J.L.Lines,M.Day,J.Li,P.Sergent,R.J.Noelle,and L.Wang.2014.VISTA regulates the development of protective antitumor immunity.Cancer Res.74(7):1933.
15.Li,W.,and W.R.Green.The role of CD4+ T cells in the pathogenesis of murine AIDS.J.Virol.80:5777−5789.
16.Li,W.,and W.R.Green.2011.Immunotherapy of murine retrovirus−induced acquired immunodeficiency by CD4+ T regulatory cell depletion and PD−1 blockade.J.Virol.85(24):13342−13353
17.Lines,J.L.,E.Pantazi,J.Mak,L.F.Sempere,L.Wang,S.O’Connell,S.Ceeraz,A.A.Suriawinata,S.Yan,M.S.Ernstoff,and R.J.Noelle.2014.VISTA is an immune checkpoint molecule for human T cells.Cancer Res.74(7):1924−32.
18.Macatangay,B.J.C.,A.L.Landay,and C.R.Rinaldo.2012.MDSC:a new player in HIV immunopathogenesis.AIDS.26:1567−1569
19.Mencacci,A.,C.Montagnol i,A.Bacci,E.Cenci,L.Pitzurra,A.Spreca,M.Kopf,A.H.Sharpe,and L.Romani.2002.CD80+Gr−1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis.J.Immunol.169:3180−3190.
20.Ostrand−Rosenberg,S.2010.Myeloid−derived suppressor cells:more mechanisms for inhibiting antitumor immunity.Cancer Immunol.Immunother.59:1593−1600.
21.Peranzoni,E.,S.Zilo,I.Marigo,L.Dolcetti,P.Zanovello,S.Mandruzzato,and V.Bronte.2010.Myeloid−derived suppressor cell heterogeneity and subset definition.Curr.Opin.Immunol.22:238−244.
22.Piccirillo,C.A.,and E.M.Shevach.2004.Naturally−occurring CD4+CD25+ immunoregulatory T cells:central players in the arena of peripheral tolerance.Semin.Immunol.16:81−88.
23.Sakaguchi,S.,N.Sakaguchi,J.Shimizu,S.Yamazaki,T.Sakihama,M.Itoh,Y.Kuniyasu,T.Nomura,M.Toda,and T.Takahashi.2001.Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells:their common role in controlling autoimmunity,tumor immunity,and transplantation tolerance.Immunol.Rev.182:18−32.
24.Qin,A.,W.Cai,T.Pan,K.Wu,Q.Yang,N.Wang,Y.Liu,D.Yan,F.Hu,P.Guo,X.Chen,L.Chen,H.Zhang,X.Tang,and J.Zhou.2013.Expansion of Monocytic Myeloid−derived suppressor cells dampens T cell function in HIV−1−seropositive individuals.J.Virol.87:1477−1490.Rowe,W.P.,W.E.Pugh,and J.W.Hartley.1970.Plaque assay techniques for murine leukemia viruses.Virol.42:1136.
25.Simard,C,S.J.Klein,T.Mak,and P.Jolicoeur.1997.Studies of the susceptibility of nude,CD4 knockout,and SCID mutant mice to the disease induced by the murine AIDS defective virus.J.Virol.71:3013−3022
26.Takamura,S.,S.Tsuji−Kawahara,H.Yagita,H.Akiba,M.Sakamoto,T.Chikaishi,M.Kato,and M.Miyazawa.2010.Premature terminal exhaustion of Friend virus−specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors.J.Immunol.184(9):4696−4707.
27.Velu,V.,K.Titanji,B.Zhu ,S.Husain,A.Pladevega,L.Lai,T.H.Vanderford,L.Chennareddi,G.Silvestri,G.J.Freeman,R.Ahmed,and R.Amara.2009.Enhancing SIV−specific immunity in vivo by PD−1 blockade.Nature.458:206−210.
28.Vollbrecht,T.,R.Stirner,A.Tufman,J.Roider,R.M.Huber,J.R.Bogner,A.Lechner,C.Bourquin,and R.Draenert.2012.Chronic progressive HIV−1 infection is associated with elevated levels of myeloid−derived suppressor cells.AIDS.26(12):F31−37.
29.Vosin,M.B.,D.Buzoni−Gatel,D.Bout,and F.Velge−Roussel.2004.Both expansion of regulatory Gr−1+CD11b+ myeloid cells and anergy of T lymphocytes participate in hyporesponsiveness of the lung−associated immune system during acute toxoplasmosis.Infect.Immun.72:5487−5492.
30.Walker,J.D.,I.Sehgal,and K.G.Kousoulas.2011.Oncolytic herpes simplex virus 1 encoding 15−prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice.J.Virol.85:7363−7371.
31.Wang,L.,R.Rubinstein,J.L.Lines,A.Wasiuk,C.Ahonen,Y.Guo,L.Lu,D.Gondek,Y.Wang,R.A.Fava,A.Fiser,S.Almo,and R.J.Noelle.2011.VISTA,a novel super family ligand that negatively regulates T cell responses.J.Exp.Med.208(3):577−92.
32.Willmon,C.,R.M.Diaz,P.Wongthida,F.Galivo,T.Kottke,J .Thompson,S.Albelda,K.Harrington,A.Melcher,and R.Vile.2011.Vesicular stomatitis virus−induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.Mol.Ther.19(1):140−149.
33.Yetter,R.A.,R.M.L.Buller,J.S.Lee,K.L.Elkins,D.E.Mosier,T.N.Fredrickson,and H.C.Morse III.1988.CD4+ T cells are required for development of a murine retrovirus−induced immunodeficiency syndrome(MAIDS).J.Exp.Med.168:623−635.
34.Youn,J.,D.I.Gabrilovich.2010.The biology of myeloid−derived suppressor cells:the blessing and the curse of morphological and functional heterogeneity.Eur.J.Immunol.40:2969−2975.
35.Zelinsky,G.,K.K.Dietze,Y.P.Husecken,S.Schimmer,S.Nair,T.Werner,K.Gibbert,O.Kershaw,A.D.Gruber,T.Sparwasser,and U.Dittmer.2009.The regulatory T−cell response during acute retroviral infection is locally defined and controls the magnitude and duration of the virus−specific cytotoxic T−cell response.Blood.114:3199−3207.
Claims (40)
- 必要とする対象における、VISTAが媒介する液性免疫阻害の阻害方法または無効化方法であって、VISTAアンタゴニストの投与を含む前記方法。
- B細胞免疫が抑制される癌または感染性疾患状態を有する対象の治療のために使用される、請求項1に記載の方法。
- 必要とする対象における、VISTAが媒介する液性免疫阻害の促進方法または増加方法であって、VISTAアゴニストの投与を含む前記方法。
- B細胞応答または抗体応答が疾患病理に関与する、自己免疫性状態、アレルギー性状態、炎症性状態、または感染性状態を有する対象の治療のために使用される、請求項3に記載の方法。
- 必要とする対象における、限定はされないが、抗原特異的な抗体応答を含む、B細胞増殖またはB細胞応答の抑制方法であって、VISTAアゴニストの投与を含む前記方法。
- B細胞応答または抗体応答が疾患病理に関与する、自己免疫性状態、アレルギー性状態、炎症性状態、または感染性状態を有する対象の治療のために使用される、請求項5に記載の方法。
- 必要とする対象における、限定はされないが、抗原特異的な抗体応答を含む、B細胞増殖またはB細胞応答の増加方法であって、VISTAアンタゴニストの投与を含む前記方法。
- B細胞免疫が抑制される癌または感染性疾患状態を有する対象の治療のために使用される、請求項7に記載の方法。
- 抗原または治療抗体に対して誘発される液性免疫応答の促進方法であって、VISTAアンタゴニストの使用を含む治療レジメンにおける、そのような抗原または抗体の投与を含む前記方法。
- 前記抗原が、腫瘍抗原、自己抗原、アレルゲン、または感染病原体の抗原である、請求項9に記載の方法。
- 前記抗体が、腫瘍抗原、自己抗原、アレルゲン、または感染病原体の抗原に対して特異的である、請求項9に記載の方法。
- 治療ワクチンまたは予防ワクチンによって誘発される液性免疫応答の促進方法であって、VISTAアンタゴニストの使用を含む治療レジメンにおける、そのようなワクチンの投与を含む前記方法。
- 前記ワクチンが、腫瘍抗原、自己抗原、アレルゲン、または感染病原体の抗原を含む、請求項12に記載の方法。
- iNOS/NO阻害物質の投与をさらに含む、請求項1〜13のいずれか1項に記載の方法。
- iNOS/NO促進物質、または一酸化窒素もしくは一酸化窒素を含む化合物の投与をさらに含む、請求項1〜13のいずれか1項に記載の方法。
- 前記iNOS/NO阻害物質が、一酸化窒素を阻害する化合物であるか、または一酸化窒素の合成を阻害する化合物である、請求項14に記載の方法。
- 前記iNOS/NO阻害物質が、一酸化窒素を促進する化合物であるか、または一酸化窒素の合成を促進する化合物である、請求項14に記載の方法。
- 前記化合物が、任意選択で、NG−ニトロ−L−アルギニンメチルエステル、NG−エチル−L−アルギニン、N−イミノエチル−L−アルギニン、L−NG−メチルアルギニン、及びNG−ニトロ−L−アルギニンであるアルギニン誘導体であるか、または前記阻害物質が、NG−ニトロ−Lアルギニンメチルエステルである、請求項17に記載の方法。
- 前記化合物が、ロバスタチン、フェニル酢酸のナトリウム塩(NaPA)、FPT阻害物質II、N−アセチルシステイン(NAC)、及びcAMPであるか、またはこれらのすべてが、参照によって、それらの全体がここに組み込まれる、米国第6,586,474号、第6,545,170号、第6,593,372号、第6,787,668号、第6,809,117号、第6,591,889号、第7,196,118号、第7,049,058号において開示されているiNOS/NO阻害物質のいずれかである、請求項17に記載の方法。
- 前記VISTAアンタゴニストが、抗VISTA抗体またはVISTAの断片である、請求項1〜19のいずれかに記載の方法。
- 前記iNOS/NO阻害物質が、L−NMAまたはLNMMAである、先行請求項のいずれかに記載の方法。
- 前記VISTAアゴニストが、アゴニストである抗ヒトVISTA抗体または抗ヒトVISTA抗体断片またはVISTA−Ig結合体またはVISTAの多量体形態である、先行請求項のいずれかに記載の方法。
- 前記VISTA−Igが、任意選択で、少なくとも1つのエフェクター機能の減弱または増加のために改変され得る、IgG1、IgG2、IgG3、またはIgG4のFc領域またはその断片を含む、請求項22に記載の方法。
- 前記対象が、癌または感染性疾患を有する、先行請求項のいずれかに記載の方法。
- 前記対象が、レトロウイルスなどのウイルス、細菌、または寄生虫によって引き起こされる感染性疾患を有する、先行請求項のいずれかに記載の方法。
- 前記対象が、進行した癌もしくは転移性の癌を有し、及び/または固形腫瘍を有する、先行請求項のいずれかに記載の方法。
- 前記癌が、肉腫、黒色腫、卵巣癌、肺癌、リンパ腫、白血病、または骨髄性の癌である、請求項26に記載の方法。
- 前記VISTAアゴニストまたはVISTAアンタゴニストが、未変化の抗VISTA抗体または抗VISTA抗体断片である、先行請求項に記載の方法。
- 前記抗体が、ヒトのものであるか、またはヒト化されたものである、請求項28に記載の方法。
- 前記抗体が、ヒトFc領域を含む請求項28に記載の方法。
- 前記Fc領域が、IgG1、IgG2、IgG3、またはIgG4のものである、請求項30に記載の方法。
- 前記Fc領域に変異が導入され、補体との結合、FcRとの結合、ADCC、糖鎖修飾、または半減期を阻害または増進する、請求項28に記載の方法。
- PD−1アゴニストもしくはPD−L1アゴニスト、またはPD−1アンタゴニストもしくはPD−L1アンタゴニストの投与をさらに含む、先行請求項のいずれかに記載の方法。
- 前記アンタゴニストが、抗PD−1抗体もしくは抗PD−L1抗体、またはPD−1融合タンパク質である、請求項33に記載の方法。
- 前記アゴニストが、抗PD−1抗体もしくは抗PD−L1抗体、またはPD−1融合タンパク質もしくはPD−L1融合タンパク質、またはPD−1もしくはPD−L1を発現する細胞である、請求項33に記載の方法。
- VISTAアンタゴニスト及びiNOS/NO阻害物質が、一緒に投与される、先行請求項のいずれかに記載の方法。
- VISTAアゴニスト及びiNOS/NO促進物質が、一緒に投与される、先行請求項のいずれかに記載の方法。
- B細胞免疫を促進するための治療レジメンにおいて、VISTAアンタゴニスト及びiNOS/NO阻害物質が別々に投与される、先行請求項のいずれかに記載の方法。
- VISTAアンタゴニストである化合物及びiNOS/NO阻害物質である化合物が、単独投与されるこうした化合物のいずれかと比較して、液性免疫に対する相乗作用を誘発するために十分な量で投与される、先行請求項のいずれかに記載の方法。
- VISTAアゴニストである化合物、及びiNOS/NO促進物質または一酸化窒素が、単独投与されるこうした化合物のいずれかと比較して、液性免疫に対する相乗作用を誘発するために十分な量で投与される、先行請求項のいずれかに記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462010736P | 2014-06-11 | 2014-06-11 | |
US62/010,736 | 2014-06-11 | ||
PCT/US2015/035371 WO2015191881A2 (en) | 2014-06-11 | 2015-06-11 | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020107224A Division JP7026169B2 (ja) | 2014-06-11 | 2020-06-22 | 液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017517578A true JP2017517578A (ja) | 2017-06-29 |
JP2017517578A5 JP2017517578A5 (ja) | 2018-07-19 |
JP6997619B2 JP6997619B2 (ja) | 2022-01-17 |
Family
ID=54834563
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017517210A Active JP6997619B2 (ja) | 2014-06-11 | 2015-06-11 | 液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用 |
JP2020107224A Active JP7026169B2 (ja) | 2014-06-11 | 2020-06-22 | 液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020107224A Active JP7026169B2 (ja) | 2014-06-11 | 2020-06-22 | 液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11123426B2 (ja) |
EP (1) | EP3154585B1 (ja) |
JP (2) | JP6997619B2 (ja) |
CN (1) | CN107073109B (ja) |
AU (1) | AU2015274504B2 (ja) |
CA (1) | CA2951885C (ja) |
MX (2) | MX2016016310A (ja) |
WO (1) | WO2015191881A2 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3079122A1 (en) | 2010-03-26 | 2011-09-29 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
WO2013192504A1 (en) * | 2012-06-22 | 2013-12-27 | The Trustees Of Dartmouth College | Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
CN109793893B (zh) | 2012-09-07 | 2023-05-26 | 达特茅斯大学理事会 | 用于诊断和治疗癌症的vista调节剂 |
EP4043493A1 (en) | 2013-12-24 | 2022-08-17 | Janssen Pharmaceutica NV | Anti-vista antibodies and fragments |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
US11123426B2 (en) | 2014-06-11 | 2021-09-21 | The Trustees Of Dartmouth College | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
WO2016090347A1 (en) | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
MX2017016647A (es) | 2015-06-24 | 2019-04-25 | Janssen Pharmaceutica Nv | Anticuerpos y fragmentos anti-vista. |
CA2994241A1 (en) | 2015-07-31 | 2017-02-09 | University Of Florida Research Foundation, Inc. | Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer |
MX2018009800A (es) | 2016-02-12 | 2018-11-09 | Janssen Pharmaceutica Nv | Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos. |
CA3020848A1 (en) | 2016-04-15 | 2017-10-19 | Janssen Pharmaceuticals, Inc. | Anti-human vista antibodies and use thereof |
KR102630011B1 (ko) | 2017-01-11 | 2024-01-26 | 브리스톨-마이어스 스큅 컴퍼니 | Psgl-1 길항제 및 그의 용도 |
AU2018236218A1 (en) | 2017-03-14 | 2019-09-12 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic pH |
US20190300610A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
GB201814562D0 (en) | 2018-09-07 | 2018-10-24 | Hummingbird Bioscience Pte Ltd | Vista antigen-binding molecules |
KR20210031722A (ko) | 2018-07-11 | 2021-03-22 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
CN114729043A (zh) * | 2019-09-19 | 2022-07-08 | 百时美施贵宝公司 | 在酸性pH下结合至VISTA的抗体 |
JP2023523589A (ja) * | 2020-04-22 | 2023-06-06 | イミューンネクスト・インコーポレイテッド | 抗ヒトvista抗体及びその使用 |
WO2022036196A2 (en) * | 2020-08-14 | 2022-02-17 | The Trustees Of Dartmouth College | Use of vista agonist for treatment/prevention of cytokine storm or crs or sepsis and/or acute or chronic respiratory distress syndrome (rds) |
CN113413464A (zh) * | 2021-08-09 | 2021-09-21 | 中国人民解放军海军军医大学第一附属医院 | 抗pd-l1抗体在急性呼吸窘迫综合征治疗药物中的应用 |
WO2024121380A1 (en) | 2022-12-08 | 2024-06-13 | Pierre Fabre Medicament | Vaccinal composition and adjuvant |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013527144A (ja) * | 2010-03-26 | 2013-06-27 | トラスティーズ・オブ・ダートマス・カレッジ | Vista制御性t細胞メディエータタンパク質、vista結合剤、およびその使用 |
Family Cites Families (227)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
JP2874751B2 (ja) | 1986-04-09 | 1999-03-24 | ジェンザイム・コーポレーション | 希望する蛋白質をミルク中へ分泌する遺伝子移植動物 |
US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5763266A (en) | 1989-06-15 | 1998-06-09 | The Regents Of The University Of Michigan | Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells |
DE3923279A1 (de) | 1989-07-14 | 1990-01-18 | Will W Prof Dr Minuth | Minusheets ist ein neues produkt, um zellen in beliebigen behaeltnissen in hochdifferenzierter form auf einer moeglichst natuerlichen unterlage zu kultivieren |
WO1991006666A1 (en) | 1989-11-06 | 1991-05-16 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5521288A (en) | 1990-03-26 | 1996-05-28 | Bristol-Myers Squibb Company | CD28IG fusion protein |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
US5547853A (en) | 1991-03-12 | 1996-08-20 | Biogen, Inc. | CD2-binding domain of lymphocyte function associated antigen 3 |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US6172208B1 (en) | 1992-07-06 | 2001-01-09 | Genzyme Corporation | Oligonucleotides modified with conjugate groups |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
CA2148252C (en) | 1992-10-30 | 2007-06-12 | Roger Brent | Interaction trap system for isolating novel proteins |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
GB9302660D0 (en) | 1993-02-10 | 1993-03-24 | Sihra Kirpal S | A building system |
WO1994021293A1 (en) | 1993-03-19 | 1994-09-29 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
EP0700430B1 (en) | 1993-06-04 | 2005-04-20 | The United States of America as Represented by the Secretary of the Navy | Methods for selectively stimulating proliferation of t cells |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
EP0728139B1 (en) | 1993-09-03 | 2003-08-13 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
CA2195557C (en) | 1994-08-12 | 2006-10-17 | Shui-On Leung | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5801155A (en) | 1995-04-03 | 1998-09-01 | Epoch Pharmaceuticals, Inc. | Covalently linked oligonucleotide minor grove binder conjugates |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
US5985653A (en) | 1995-06-07 | 1999-11-16 | Aastrom Biosciences, Inc. | Incubator apparatus for use in a system for maintaining and growing biological cells |
US6096532A (en) | 1995-06-07 | 2000-08-01 | Aastrom Biosciences, Inc. | Processor apparatus for use in a system for maintaining and growing biological cells |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
GB9517780D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
GB9517779D0 (en) | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
US6444806B1 (en) | 1996-04-30 | 2002-09-03 | Hisamitsu Pharmaceutical Co., Inc. | Conjugates and methods of forming conjugates of oligonucleotides and carbohydrates |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
US6593372B2 (en) | 1996-11-13 | 2003-07-15 | Cold Spring Harbor Laboratory | Therapeutic uses for nitric oxide inhibitors |
US5977181A (en) | 1996-11-13 | 1999-11-02 | Cold Spring Harbor Laboratory | Therapeutic uses for nitric oxide inhibitors |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US20060084082A1 (en) | 1997-03-07 | 2006-04-20 | Human Genome Sciences, Inc. | 186 human secreted proteins |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
US6982323B1 (en) | 1997-12-23 | 2006-01-03 | Alexion Pharmaceuticals, Inc. | Chimeric proteins for diagnosis and treatment of diabetes |
US6006758A (en) | 1998-02-03 | 1999-12-28 | University Of Maryland | Method and device for the detection and removal of head lice |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2340112T3 (es) | 1998-04-20 | 2010-05-28 | Glycart Biotechnology Ag | Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos. |
US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
DE69936453T2 (de) | 1998-07-28 | 2008-03-06 | The Regents Of The University Of California, Oakland | Für einen g-protein gekoppelten rezeptor, der an der empfindungstransduktion beteiligt ist, kodierende nukleinsäuren |
US20030096955A1 (en) | 1998-09-01 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7081514B2 (en) | 1998-09-01 | 2006-07-25 | Genentech, Inc. | PRO1347 polypeptides |
US6335437B1 (en) | 1998-09-07 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Methods for the preparation of conjugated oligomers |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
CA2352286C (en) | 1998-11-24 | 2011-07-12 | Bristol-Myers Squibb Company | Intracellular targeted delivery of compounds by 70 kd heat shock protein |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
US6696686B1 (en) | 1999-06-06 | 2004-02-24 | Elgems Ltd. | SPECT for breast cancer detection |
CA2377513A1 (en) | 1999-06-25 | 2001-01-04 | Universitat Zurich | Hetero-associating coiled-coil peptides |
WO2001001137A1 (en) | 1999-06-30 | 2001-01-04 | Children's Medical Center Corporation | Fusion protein and uses thereof |
US7754855B1 (en) | 1999-07-13 | 2010-07-13 | Bolder Biotechnology, Inc. | Immunoglobulin fusion proteins |
EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
KR100942863B1 (ko) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
US6395437B1 (en) | 1999-10-29 | 2002-05-28 | Advanced Micro Devices, Inc. | Junction profiling using a scanning voltage micrograph |
NZ520813A (en) | 2000-03-24 | 2004-05-28 | Pharmacia Corp | Amidino compounds useful as nitric oxide synthase inhibitors |
KR20020093029A (ko) | 2000-04-11 | 2002-12-12 | 제넨테크, 인크. | 다가 항체 및 그의 용도 |
US6545170B2 (en) | 2000-04-13 | 2003-04-08 | Pharmacia Corporation | 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
US6559279B1 (en) | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
EP2149604A1 (en) | 2000-09-08 | 2010-02-03 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
WO2002029072A2 (en) | 2000-10-06 | 2002-04-11 | Novartis Ag | Targetting molecules for adenoviral vectors |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
US6828112B2 (en) | 2001-01-04 | 2004-12-07 | Myriad Genetics, Inc. | Method of detecting protein-protein interactions |
US20050063948A1 (en) | 2001-03-08 | 2005-03-24 | Dickerson Erin B. | Methods for targeting interleukin-12 to malignant endothelium |
AU2002338265A1 (en) | 2001-03-28 | 2002-10-15 | Incyte Genomics, Inc. | Molecules for disease detection and treatment |
ITTV20010035A1 (it) | 2001-03-30 | 2002-09-30 | Bettio Group Srl | Zanzariera con dispositivo di aggancio e sgancio rapido della barra maniglia |
WO2002092780A2 (en) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
KR101021124B1 (ko) | 2001-05-24 | 2011-03-14 | 지모제넥틱스, 인코포레이티드 | Taci-면역글로불린 융합 단백질 |
US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
CA2763913C (en) | 2001-08-10 | 2014-10-28 | Aberdeen University | Antigen binding domains |
US6797493B2 (en) | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
WO2003077947A1 (en) | 2002-03-15 | 2003-09-25 | Schering Corporation | Methods of modulating cd200 receptors |
CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
GB2392158B (en) | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
JP2006512910A (ja) | 2002-10-23 | 2006-04-20 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | A34およびa33様3dna、タンパク質、それらに対する抗体、ならびに同一物を使用した治療方法 |
CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
DE602004018141D1 (de) | 2003-07-04 | 2009-01-15 | Affibody Ab | Polypeptide mit bindungsaffinität für her2 |
AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
US20050256576A1 (en) | 2004-05-13 | 2005-11-17 | Moskowitz Nathan C | Artificial expansile total lumbar and thoracic discs for posterior placement without supplemental instrumentation and its adaptation for anterior placement of artificial cervical, thoracic and lumbar discs |
WO2005113606A2 (en) | 2004-05-13 | 2005-12-01 | Eli Lilly And Company | Fgf-21 fusion proteins |
US7919585B2 (en) | 2004-06-24 | 2011-04-05 | Mayo Foundation For Medical Education And Research | B7-H5, a costimulatory polypeptide |
JP5948627B2 (ja) | 2004-10-29 | 2016-07-20 | レイショファーム ゲーエムベーハー | 線維芽細胞成長因子(fgf)のリモデリングと糖質ペグ化 |
ES2545533T3 (es) | 2004-11-01 | 2015-09-11 | The Regents Of The University Of California | Composiciones y métodos para modificación de biomoléculas |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
US8231872B2 (en) | 2005-04-25 | 2012-07-31 | The Trustees Of Dartmouth College | Regulatory T cell mediator proteins and uses thereof |
US8236304B2 (en) | 2005-04-25 | 2012-08-07 | Trustees Of Dartmouth College | Use of PD-L3 proteins and PD-L3 specific antibodies or antibody fragments to regulate CD4+ and CD8+ T cell immunity |
US8652465B2 (en) | 2005-06-08 | 2014-02-18 | Emory University | Methods and compositions for the treatment of persistent infections |
WO2007030198A2 (en) | 2005-07-11 | 2007-03-15 | Human Biosystems | Improved methods and solutions for storing donor organs |
US7531164B2 (en) * | 2005-10-21 | 2009-05-12 | Duke University | Preventing bacterial or viral infectivity and composition containing infection preventing additive |
US20070219208A1 (en) * | 2006-02-27 | 2007-09-20 | Balaraman Kalyanaraman | Methods for Treating Cancer |
US7655778B2 (en) | 2006-02-28 | 2010-02-02 | Curonix Co., Ltd. | SISP-1, a novel p53 target gene and use thereof |
WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
US20110158995A1 (en) | 2008-07-28 | 2011-06-30 | Renault S.A.S | Multi-Specific Binding Proteins Targeting B Cell Disorders |
US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
AU2009298122B2 (en) | 2008-10-03 | 2015-01-15 | Emory University | Agonists of toll-like receptor 5 for the treatment of graft-versus-host disease |
US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
US20180237525A9 (en) | 2010-03-26 | 2018-08-23 | Randolph J. Noelle | VISTA Agonist and Methods of Use |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
US20110243943A1 (en) | 2010-04-02 | 2011-10-06 | Athena Discovery, Inc. | Treatment using relaxin-fusion proteins with extended in vivo half-lives |
JP2015520192A (ja) | 2012-06-06 | 2015-07-16 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Hippo経路を調節する結合剤およびその使用 |
WO2013192504A1 (en) * | 2012-06-22 | 2013-12-27 | The Trustees Of Dartmouth College | Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
CN109793893B (zh) | 2012-09-07 | 2023-05-26 | 达特茅斯大学理事会 | 用于诊断和治疗癌症的vista调节剂 |
SG10201709715RA (en) | 2013-05-24 | 2017-12-28 | Medimmune Llc | Anti-b7-h5 antibodies and their uses |
EP4043493A1 (en) | 2013-12-24 | 2022-08-17 | Janssen Pharmaceutica NV | Anti-vista antibodies and fragments |
EP3094346B1 (en) | 2014-01-14 | 2019-12-11 | The Trustees Of Dartmouth College | Vista antagonist and methods of use |
KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
US11123426B2 (en) | 2014-06-11 | 2021-09-21 | The Trustees Of Dartmouth College | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
WO2016090347A1 (en) | 2014-12-05 | 2016-06-09 | Immunext, Inc. | Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators |
WO2017181109A1 (en) | 2016-04-15 | 2017-10-19 | Michael Molloy | Anti-human vista antibodies and use thereof |
CA3020848A1 (en) | 2016-04-15 | 2017-10-19 | Janssen Pharmaceuticals, Inc. | Anti-human vista antibodies and use thereof |
US11649285B2 (en) | 2016-08-03 | 2023-05-16 | Bio-Techne Corporation | Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy |
-
2015
- 2015-06-11 US US15/317,552 patent/US11123426B2/en active Active
- 2015-06-11 JP JP2017517210A patent/JP6997619B2/ja active Active
- 2015-06-11 AU AU2015274504A patent/AU2015274504B2/en active Active
- 2015-06-11 EP EP15806089.7A patent/EP3154585B1/en active Active
- 2015-06-11 MX MX2016016310A patent/MX2016016310A/es unknown
- 2015-06-11 CA CA2951885A patent/CA2951885C/en active Active
- 2015-06-11 WO PCT/US2015/035371 patent/WO2015191881A2/en active Application Filing
- 2015-06-11 CN CN201580042949.0A patent/CN107073109B/zh active Active
-
2016
- 2016-12-08 MX MX2022001143A patent/MX2022001143A/es unknown
-
2020
- 2020-06-22 JP JP2020107224A patent/JP7026169B2/ja active Active
-
2021
- 2021-08-16 US US17/402,973 patent/US20220040298A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013527144A (ja) * | 2010-03-26 | 2013-06-27 | トラスティーズ・オブ・ダートマス・カレッジ | Vista制御性t細胞メディエータタンパク質、vista結合剤、およびその使用 |
Non-Patent Citations (4)
Title |
---|
CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 60, no. 12, JPN6019010183, 2011, pages 1729 - 1738, ISSN: 0004376612 * |
CANCER RESEARCH, vol. 74, no. 7, JPN6019010181, April 2014 (2014-04-01), pages 1933 - 1944, ISSN: 0004376610 * |
JOURNAL OF VIROLOGY, vol. 87, no. 4, JPN6019010182, 2013, pages 2058 - 2071, ISSN: 0004376611 * |
日本薬理学雑誌, vol. 119, no. 1, JPN6020041491, 2002, pages 29 - 35, ISSN: 0004376613 * |
Also Published As
Publication number | Publication date |
---|---|
EP3154585B1 (en) | 2022-02-23 |
WO2015191881A3 (en) | 2016-03-03 |
US11123426B2 (en) | 2021-09-21 |
WO2015191881A9 (en) | 2016-04-21 |
CA2951885C (en) | 2023-07-04 |
AU2015274504B2 (en) | 2021-02-04 |
AU2015274504A1 (en) | 2017-01-12 |
WO2015191881A2 (en) | 2015-12-17 |
US20220040298A1 (en) | 2022-02-10 |
CN107073109A (zh) | 2017-08-18 |
EP3154585A4 (en) | 2017-12-06 |
JP6997619B2 (ja) | 2022-01-17 |
JP7026169B2 (ja) | 2022-02-25 |
CN107073109B (zh) | 2021-08-06 |
MX2016016310A (es) | 2017-10-20 |
JP2020169192A (ja) | 2020-10-15 |
US20170119877A1 (en) | 2017-05-04 |
EP3154585A2 (en) | 2017-04-19 |
MX2022001143A (es) | 2022-02-16 |
CA2951885A1 (en) | 2015-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7026169B2 (ja) | 液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用 | |
JP7270001B2 (ja) | Mhcクラスii拘束性mage-a3を認識するt細胞受容体 | |
JP6917952B2 (ja) | 癌の診断および治療のためのvista調節剤 | |
JP6665139B2 (ja) | 新規VISTA−Igコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのVISTA−Igの使用 | |
US20240075070A1 (en) | Chimeric antigen receptor t cells targeting the tumor microenvironment | |
JP2021176326A (ja) | 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法 | |
JP6246158B2 (ja) | 免疫関連疾患の治療のための新規組成物と方法 | |
CN107098958B (zh) | Vista调节性t细胞介体蛋白、vista结合剂及其用途 | |
US20210038646A1 (en) | Chimeric antigen receptors targeting the tumor microenvironment | |
JP2019531056A (ja) | 融合タンパク質を使用したtcrの再プログラム化のための組成物及び方法 | |
JP2017533207A (ja) | Slamf1アンタゴニスト及びその使用 | |
KR20220036941A (ko) | 암 및 기타 질환의 치료를 위한 알파3베타1 인테그린 표적화 | |
KR20230020421A (ko) | Cd70 특이적 융합 단백질을 사용하는 tcr 재프로그래밍을 위한 조성물 및 방법 | |
JP2023520572A (ja) | オルソゴナルな受容体を発現するようにゲノムが改変されたヒト免疫細胞 | |
KR20220115572A (ko) | 항-b7-h3 단클론성 항체 및 이의 사용 방법 | |
CN108290940B (zh) | Tcr及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180611 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180611 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190325 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190625 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190826 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190925 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200622 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200622 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20200707 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200831 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20200901 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20201030 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20201104 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20210406 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20210517 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210816 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211007 |
|
C23 | Notice of termination of proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C23 Effective date: 20211025 |
|
C03 | Trial/appeal decision taken |
Free format text: JAPANESE INTERMEDIATE CODE: C03 Effective date: 20211118 |
|
C30A | Notification sent |
Free format text: JAPANESE INTERMEDIATE CODE: C3012 Effective date: 20211118 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211217 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6997619 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |